| Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity S Howard, V Berdini, JA Boulstridge, MG Carr, DM Cross, J Curry, ... Journal of medicinal chemistry 52 (2), 379-388, 2009 | 399 | 2009 |
| Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation AL Gill, M Frederickson, A Cleasby, SJ Woodhead, MG Carr, ... Journal of medicinal chemistry 48 (2), 414-426, 2005 | 242 | 2005 |
| The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non‐small cell lung cancer B Graham, J Curry, T Smyth, L Fazal, R Feltell, I Harada, J Coyle, ... Cancer science 103 (3), 522-527, 2012 | 91 | 2012 |
| The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and-resistant gastrointestinal stromal tumor models T Smyth, T Van Looy, JE Curry, AM Rodriguez-Lopez, A Wozniak, M Zhu, ... Molecular cancer therapeutics 11 (8), 1799-1808, 2012 | 74 | 2012 |
| Pharmaceutical Compounds JE Curry, JF Lyons, MS Squires, NT Thompson, KM Thompson, PG Wyatt US Patent App. 11/814,461, 2009 | 73 | 2009 |
| Fragment-based discovery of potent and selective DDR1/2 inhibitors CW Murray, V Berdini, IM Buck, ME Carr, A Cleasby, JE Coyle, JE Curry, ... ACS medicinal chemistry letters 6 (7), 798-803, 2015 | 69 | 2015 |
| Aurora B kinase inhibition in mitosis: strategies for optimizing the use of aurora kinase inhibitors such as AT9283 J Curry, H Angove, L Fazal, J Lyons, M Reule, N Thompson, N Wallis Cell Cycle 8 (12), 1921-1929, 2009 | 65 | 2009 |
| A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation KC Chan, CM Ting, PS Chan, MC Lo, KW Lo, JE Curry, T Smyth, ... Molecular cancer 12, 1-15, 2013 | 60 | 2013 |
| AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders MA Dawson, JE Curry, K Barber, PA Beer, B Graham, JF Lyons, ... British journal of haematology 150 (1), 46-57, 2010 | 58 | 2010 |
| The early development of corticobulbar and corticospinal systems: studies using the North American opossum GF Martin, T Cabana, JL Culberson, JJ Curry, I Tschismadia Anatomy and Embryology 161, 197-213, 1980 | 55 | 1980 |
| Human amniotic fluid lacks interleukin‐2 and interleukin‐15 but can interact with the β‐chain of the interleukin‐2 receptor RF Searle, SJ Bromage, J Palmer, JE Curry, AK Lang Immunology 99 (3), 411-417, 2000 | 18 | 2000 |
| Preclinical evaluation of DISC‐GMCSF for the treatment of breast carcinoma PT Loudon, CS McLean, G Martin, J Curry, M Leigh Shaw, C Hoogstraten, ... The Journal of Gene Medicine: A cross‐disciplinary journal for research on …, 2003 | 11 | 2003 |
| JAK2 and T315I Abl activity of clinical candidate, AT9283 J Lyons, J Curry, K Mallet, D Miller, M Reule, L Sevears, D Tisi, N Wallis Cancer Research 67 (9_Supplement), 5747-5747, 2007 | 7 | 2007 |
| DISC-GMCSF for immunotherapy of metastatic melanoma—preclinical and clinical use of HSV for gene delivery P Loudon, M Boursnell, E Choolun, J Curry, D Day, I Duncan, C Entwisle, ... European Journal of Cancer, S86, 2001 | | 2001 |
| Phase I clinical trial of DISC-GMCSF for immunotherapy of metastatic melanoma PT Loudon, E Choolun, J Curry, DA Day, IA Duncan, C Entwisle, ... Cancer Gene Therapy 8, 2001 | | 2001 |
